PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid Exposure (PHOENIX-ECP)
PHOENIX- A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis or Hepatitis With Inadequate Response to Corticosteroids in Participants With Unresectable or Metastatic Melanoma Treated With Immune Checkpoint Inhibitors (ICI)
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy in which the photoactivating agent methoxsalen (also known as UVADEX) is used in combination with ultraviolet A (UVA) light.
Immune checkpoint inhibitor therapy is widely used for the treatment of several cancers, including melanoma. However, a common immune-related adverse event associated with this therapy is Immune-related colitis or hepatitis. Corticosteroids are typically the first-line treatment for this condition, but some participants do not respond adequately.
The purpose of this study is to evaluate the efficacy of ECP in the treatment of immune-related (ir)-colitis and ir-hepatitis with inadequate response to corticosteroids, and to compare its efficacy to other second-line immunosuppressant therapies. The ECP procedure in this study is performed using the CELLEX® device, a fully closed-loop extracorporeal blood circulation device. The CELLEX device is used in conjunction with methoxsalen.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Therakos TKS2001 Study Team
- 電話番号:855-512-3327
- メール:Clinicaltrials@therakos.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Participants diagnosed with unresectable or metastatic melanoma ( Stage III and Stage IV) received ICI treatment (e.g., anti-PD-1, anti-PD-L1, anti-LAG-3, anti-CTLA-4 antibody, as ICI monotherapy or ICI combination therapy) and ICI paused or discontinued because of the development of ir-colitis or ir-hepatitis.
- Participants diagnosed with ir-colitis and/or ir-hepatitis with a severity of Grade 2 or higher, based on ASCO Guidelines (
- Participants with endoscopic evidence of ir-colitis
- Participants with inadequate response to corticosteroids, as defined per protocol
- Participants who have Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
Exclusion Criteria:
- Presence of irAEs in addition to and other than ir-colitis and/or ir-hepatitis, with a higher severity grade than the irAE for inclusion (ir-colitis/ir-hepatitis) based on ASCO guidelines.
- Participant has a diagnosis of uveal melanoma as the sole melanoma subtype
- Treatment of ir-colitis or ir-hepatitis with any systemic therapy other than corticosteroids
- Concurrent conditions which may require treatment with high dose corticosteroid (> 1 milligram per kilogram per day [mg/kg/day]) and interfere with the corticosteroid tapering schedule recommended by the protocol.
- Pre-existing liver disease
- Active alcohol use disorder
- Concomitant treatment with any chemotherapy or targeted therapy for the treatment of unresectable or metastatic melanoma.
- Use of any investigational agent within 5 half-lives of the investigational agent prior to randomization.
- Contraindications or known allergic reaction to any of study intervention and/or procedures
- Participants unable to tolerate the fluid shift associated with the ECP procedure.
- Positive result for active or previous viral infections: covid-19, hepatitis B/C, CMV, EBV, adenovirus
- History of previous or concurrent malignancies within the last 3 years, other than unresectable or metastatic melanoma.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Methoxsalen in Conjunction with Extracorporeal Photopheresis System (ECP)
Participants will receive methoxsalen, in conjunction with ECP
|
Sterile solution used in conjunction with CELLEX ECP
他の名前:
Methoxsalen is used in conjunction with the CELLEX ECP
他の名前:
|
|
アクティブコンパレータ:Best Available Therapy (BAT)
Participants with ir-colitis will receive either Infliximab or Vedolizumab as per the investigator's choice.
Participants with ir-hepatitis will receive Mycophenolate Mofetil (MMF) or Azathioprine as per the investigator's choice.
|
Vedolizumab will be administered intravenously
Infliximab will be administered intravenously
Mycophenolate Mofetil will be administered orally or intravenously
Azathioprine will be administered orally or intravenously
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
Proportion of Participants Who are in Steroid-free response at Week 12 for the Randomized Immune-related Adverse Event (irAE) (ir-colitis or ir-hepatitis)
時間枠:Week 12
|
Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Duration of irAE response
時間枠:Week 64
|
Time from the start of irAE response to either the relapse of irAE (if relapse occurs), or a censoring event.
|
Week 64
|
|
Progression Free Survival (PFS) for Melanoma
時間枠:Week 64
|
Week 64
|
|
|
Overall Survival (OS)
時間枠:Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least Stable Disease as Assessed by RECIST 1.1 at Week 12 and During Follow-up
時間枠:Week 12 and Week 64
|
Week 12 and Week 64
|
|
|
Proportion of Participants with Treatment-Emergent Adverse Event (TEAEs) per Common Toxicity Criteria for Adverse Events (CTCAE) v5.0
時間枠:From first dose of the study drug up to end of study (up to Week 64)
|
From first dose of the study drug up to end of study (up to Week 64)
|
|
|
Cumulative Systemic Corticosteroid Exposure From Randomization to Week 12
時間枠:Up to Week 12
|
Up to Week 12
|
|
|
Peak Dose of Systemic Corticosteroid Exposure From Randomization to Week 12
時間枠:Up to Week 12
|
Up to Week 12
|
|
|
Proportion of Participants who Completely Discontinue Systemic Corticosteroid Treatment Until Week 12
時間枠:Week 12
|
Week 12
|
|
|
Time to Complete Discontinuation of Systemic Corticosteroids for at Least 1 Week
時間枠:From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
From screening up to the first documentation of the discontinuation of systemic corticosteroid (up to Week 64)
|
|
|
Time to First Response of Randomized irAE Based on ASCO Criteria
時間枠:Week 64
|
Week 64
|
|
|
Proportion of Participants With at Least one irAE who Achieve Response (as Defined per ASCO Criteria) at Week 12
時間枠:Week 12
|
Week 12
|
|
|
Proportion of Participants With at Least One irAE That Resolves Completely (as per CTCAE v5.0) and Remains Resolved Until Week 12
時間枠:Week 12
|
Week 12
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Isabelle T Seemann, Ph.D、Therakos LLC
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
- ランダム化比較試験
- メラノーマ
- デバイス
- 転移性黒色腫
- 切除不能な黒色腫
- ECP
- 大腸炎
- 免疫関連の有害事象
- 免疫関連大腸炎
- 第2相臨床試験
- 体外フォトフェレーシス
- メトキサレン
- ステロイド抵抗性
- Immune checkpoint inhibitor toxicity
- Checkpoint inhibitor-induced colitis
- Checkpoint inhibitor-induced hepatitis
- Immune checkpoint Inhibitors
- UVADEX
- Corticosteroid refractory
- Cellex
- 8-Mop
- Ir-AE
- Ir-AE Colitis
- Ir-AE Hepatitis
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 腸の病気
- 組織型別の新生物
- 消化器系疾患
- 消化器疾患
- 肝疾患
- 結腸疾患
- 皮膚疾患
- 胃腸炎
- 神経外胚葉性腫瘍
- 新生物、生殖細胞および胚
- 新生物、神経組織
- 神経内分泌腫瘍
- 母斑とメラノーマ
- 皮膚腫瘍
- 皮膚および結合組織疾患
- 肝炎
- 大腸炎
- メラノーマ
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 硫黄化合物
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 治療
- ピラ
- 脂肪酸
- 脂質
- 外科的処置、手術
- 核酸、ヌクレオチド、およびヌクレオシド
- 酸、非環式
- カルボン酸
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- プリン
- ヌクレオシド
- クマリン
- ベンゾピランス
- カプロート
- 光療法
- 複素環化化合物、3リング
- 体外循環
- PUVA療法
- 紫外療法
- フロコマリン
- チオヌクレオシド
- メルカプトプリン
- インフリキシマブ
- ミコフェノール酸
- アザチオプリン
- メトサレン
- ヴェドリズマブ
- 光圧
その他の研究ID番号
- TKS2001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。